Intellia Therapeutics (NTLA) Stock Forecast, Price Target & Predictions
NTLA Stock Forecast
Intellia Therapeutics stock forecast is as follows: an average price target of $119.16 (represents a 439.92% upside from NTLA’s last price of $22.07) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.
NTLA Price Target
The average price target for Intellia Therapeutics (NTLA) is $119.16 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $252.00 to $24.00. This represents a potential 439.92% upside from NTLA's last price of $22.07.
NTLA Analyst Ratings
According to 13 Wall Street analysts, Intellia Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for NTLA stock is 0 'Strong Buy' (0.00%), 13 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Intellia Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Luca Issi | RBC Capital | $54.00 | $22.38 | 141.29% | 144.68% |
| Jun 24, 2024 | Dae Gon Ha | Stifel Nicolaus | $80.00 | $25.22 | 217.21% | 262.48% |
| Jun 24, 2024 | Jack Allen | Robert W. Baird | $24.00 | $26.00 | -7.67% | 8.74% |
| May 10, 2024 | Kostas Biliouris | BMO Capital | $70.00 | $24.84 | 181.80% | 217.17% |
| Feb 01, 2023 | - | Cantor Fitzgerald | $67.00 | $42.44 | 57.87% | 203.58% |
| Jan 04, 2023 | - | Wells Fargo | $120.00 | $36.64 | 227.51% | 443.72% |
| Dec 06, 2022 | - | Credit Suisse | $88.00 | $40.03 | 119.84% | 298.73% |
| Dec 02, 2022 | - | Leerink Partners | $86.00 | $45.80 | 87.77% | 289.67% |
| Nov 15, 2022 | - | Chardan Capital | $129.00 | $53.30 | 142.03% | 484.50% |
| Aug 05, 2022 | - | Leerink Partners | $152.00 | $61.98 | 145.24% | 588.72% |
The latest Intellia Therapeutics stock forecast, released on Aug 09, 2024 by Luca Issi from RBC Capital, set a price target of $54.00, which represents a 141.29% increase from the stock price at the time of the forecast ($22.38), and a 144.68% increase from NTLA last price ($22.07).
Intellia Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $52.67 | $57.00 |
| Last Closing Price | $22.07 | $22.07 | $22.07 |
| Upside/Downside | -100.00% | 138.65% | 158.27% |
In the current month, the average price target of Intellia Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Intellia Therapeutics's last price of $22.07. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 12, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 12, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Aug 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 26, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jun 24, 2024 | Wedbush | Buy | Buy | Hold |
| Jun 04, 2024 | Wedbush | Neutral | Neutral | Hold |
| Jun 04, 2024 | Citigroup | Underperform | Underperform | Hold |
| Jun 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 03, 2024 | Citigroup | Neutral | Neutral | Hold |
Intellia Therapeutics's last stock rating was published by RBC Capital on Sep 11, 2024. The company gave NTLA a "Buy" rating, the same as its previous rate.
Intellia Therapeutics Financial Forecast
Intellia Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.99M | $13.59M | $12.61M | $13.57M | $13.27M | - | $11.25M | $12.85M | $7.20M | $6.55M | $6.45M | $6.59M | $22.22M | $16.26M | $12.92M | $10.94M | $10.62M |
| Avg Forecast | $7.80M | $7.72M | $7.63M | $7.54M | $13.81M | $13.80M | $16.97M | $12.68M | $8.59M | $9.95M | $19.68M | $11.24M | $12.74M | $13.05M | $12.08M | $11.83M | $11.33M | $11.89M | $9.42M | $8.54M | $8.26M | $8.66M | $12.21M | $9.86M | $13.14M | $14.90M | $9.53M | $21.98M | $9.58M | $9.17M |
| High Forecast | $7.80M | $7.72M | $7.63M | $7.54M | $13.81M | $13.80M | $16.97M | $12.68M | $8.59M | $16.92M | $19.68M | $11.24M | $35.29M | $13.05M | $12.08M | $11.83M | $11.33M | $11.89M | $9.42M | $17.36M | $16.80M | $17.61M | $24.83M | $20.04M | $26.72M | $30.29M | $19.37M | $44.68M | $19.47M | $18.64M |
| Low Forecast | $7.80M | $7.72M | $7.63M | $7.54M | $13.81M | $13.80M | $16.97M | $12.68M | $8.59M | $4.70M | $19.68M | $11.24M | $4.81M | $13.05M | $12.08M | $11.83M | $11.33M | $11.89M | $9.42M | $2.97M | $2.87M | $3.01M | $4.25M | $3.43M | $4.57M | $5.18M | $3.31M | $7.64M | $3.33M | $3.19M |
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 6 | 7 | 7 | 7 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 1.13% | 1.07% | 1.20% | 1.12% | - | 1.32% | 1.56% | 0.83% | 0.54% | 0.65% | 0.50% | 1.49% | 1.71% | 0.59% | 1.14% | 1.16% |
Intellia Therapeutics's average Quarter revenue forecast for Dec 23 based on 10 analysts is $12.74M, with a low forecast of $4.81M, and a high forecast of $35.29M. NTLA's average Quarter revenue forecast represents a 6.28% increase compared to the company's last Quarter revenue of $11.99M (Sep 23).
Intellia Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 6 | 7 | 7 | 7 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-122.22M | $-123.68M | $-111.86M | $-104.66M | $-95.77M | - | $-142.07M | $-79.36M | $-69.86M | $-67.17M | $-44.61M | $-40.59M | $-26.24M | $-30.83M | $-30.27M | $-26.69M | $-22.25M |
| Avg Forecast | $-7.80M | $-7.72M | $-7.63M | $-7.54M | $-13.81M | $-13.80M | $-16.97M | $-12.68M | $-8.59M | $-9.95M | $-19.68M | $-133.90M | $-12.74M | $-13.05M | $-12.08M | $-121.73M | $-11.33M | $-66.00M | $-9.42M | $-110.66M | $-66.69M | $-60.00M | $-55.51M | $-42.59M | $-34.50M | $-31.57M | $-34.40M | $-16.65M | $-26.22M | $-26.92M |
| High Forecast | $-7.80M | $-7.72M | $-7.63M | $-7.54M | $-13.81M | $-13.80M | $-16.97M | $-12.68M | $-8.59M | $-4.70M | $-19.68M | $-107.12M | $-4.81M | $-13.05M | $-12.08M | $-97.38M | $-11.33M | $-52.80M | $-9.42M | $-88.53M | $-53.35M | $-48.00M | $-44.41M | $-34.07M | $-27.60M | $-25.26M | $-27.52M | $-13.32M | $-20.97M | $-21.53M |
| Low Forecast | $-7.80M | $-7.72M | $-7.63M | $-7.54M | $-13.81M | $-13.80M | $-16.97M | $-12.68M | $-8.59M | $-16.92M | $-19.68M | $-160.69M | $-35.29M | $-13.05M | $-12.08M | $-146.08M | $-11.33M | $-79.19M | $-9.42M | $-132.80M | $-80.03M | $-71.99M | $-66.61M | $-51.10M | $-41.40M | $-37.89M | $-41.28M | $-19.97M | $-31.46M | $-32.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.37% | 10.24% | 0.92% | 9.23% | 1.45% | - | 1.28% | 1.19% | 1.16% | 1.21% | 1.05% | 1.18% | 0.83% | 0.90% | 1.82% | 1.02% | 0.83% |
undefined analysts predict NTLA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Intellia Therapeutics's previous annual EBITDA (undefined) of $NaN.
Intellia Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 6 | 7 | 7 | 7 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-122.22M | $-123.68M | $-92.34M | $-116.73M | $-111.28M | - | $-149.50M | $-81.24M | $-71.64M | $-68.81M | $-46.20M | $-42.19M | $-27.84M | $-32.39M | $-31.81M | $-28.28M | $-23.63M |
| Avg Forecast | $-109.27M | $-110.92M | $-113.43M | $-119.42M | $-136.79M | $-136.49M | $-133.53M | $-135.62M | $-138.18M | $-135.37M | $-118.00M | $-136.03M | $-139.49M | $-145.32M | $-128.09M | $-123.66M | $-133.70M | $-67.68M | $-124.53M | $-112.42M | $-68.27M | $-61.53M | $-56.86M | $-44.10M | $-35.86M | $-33.50M | $-36.15M | $-17.49M | $-27.77M | $-28.59M |
| High Forecast | $-109.27M | $-110.92M | $-113.43M | $-119.42M | $-136.79M | $-136.49M | $-133.53M | $-135.62M | $-138.18M | $-103.98M | $-118.00M | $-108.82M | $-95.84M | $-117.22M | $-128.09M | $-98.93M | $-133.70M | $-54.15M | $-124.53M | $-89.94M | $-54.62M | $-49.22M | $-45.49M | $-35.28M | $-28.69M | $-26.80M | $-28.92M | $-13.99M | $-22.22M | $-22.87M |
| Low Forecast | $-109.27M | $-110.92M | $-113.43M | $-119.42M | $-136.79M | $-136.49M | $-133.53M | $-135.62M | $-138.18M | $-150.09M | $-118.00M | $-163.23M | $-157.52M | $-172.44M | $-128.09M | $-148.40M | $-133.70M | $-81.22M | $-124.53M | $-134.90M | $-81.93M | $-73.84M | $-68.23M | $-52.93M | $-43.04M | $-40.20M | $-43.38M | $-20.99M | $-33.33M | $-34.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 0.97% | 0.75% | 0.87% | 1.64% | - | 1.33% | 1.19% | 1.16% | 1.21% | 1.05% | 1.18% | 0.83% | 0.90% | 1.82% | 1.02% | 0.83% |
Intellia Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NTLA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Intellia Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 6 | 7 | 7 | 7 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $29.40M | $30.65M | $27.45M | $23.63M | $22.14M | - | $22.40M | $22.11M | $18.71M | $16.68M | $13.59M | $10.76M | $10.57M | $11.53M | $11.31M | $8.98M | $8.43M |
| Avg Forecast | $13.75M | $13.59M | $13.44M | $13.28M | $24.32M | $24.32M | $29.90M | $22.34M | $15.13M | $17.53M | $34.67M | $19.81M | $22.45M | $22.99M | $21.28M | $20.85M | $19.97M | $20.94M | $16.59M | $15.05M | $14.56M | $15.26M | $21.52M | $17.37M | $9.15M | $12.72M | $16.79M | $6.22M | $8.82M | $16.15M |
| High Forecast | $13.75M | $13.59M | $13.44M | $13.28M | $24.32M | $24.32M | $29.90M | $22.34M | $15.13M | $29.81M | $34.67M | $19.81M | $62.17M | $22.99M | $21.28M | $20.85M | $19.97M | $20.94M | $16.59M | $30.59M | $29.59M | $31.02M | $43.75M | $35.30M | $10.98M | $15.26M | $34.13M | $7.47M | $10.58M | $32.83M |
| Low Forecast | $13.75M | $13.59M | $13.44M | $13.28M | $24.32M | $24.32M | $29.90M | $22.34M | $15.13M | $8.29M | $34.67M | $19.81M | $8.48M | $22.99M | $21.28M | $20.85M | $19.97M | $20.94M | $16.59M | $5.23M | $5.06M | $5.31M | $7.49M | $6.04M | $7.32M | $10.17M | $5.84M | $4.98M | $7.05M | $5.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.28% | 1.44% | 1.32% | 1.18% | 1.06% | - | 1.49% | 1.52% | 1.23% | 0.78% | 0.78% | 1.18% | 0.83% | 0.69% | 1.82% | 1.02% | 0.52% |
Intellia Therapeutics's average Quarter SG&A projection for Dec 23 is $22.45M, based on 10 Wall Street analysts, with a range of $8.48M to $62.17M. The forecast indicates a -23.63% fall compared to NTLA last annual SG&A of $29.40M (Sep 23).
Intellia Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 7 | 11 | 7 | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 9 | 10 | 20 | 10 | 10 | 9 | 9 | 9 | 6 | 7 | 7 | 7 | 9 | 10 | 16 | 9 | 10 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.38 | $-1.40 | $-1.05 | $-1.44 | $-1.46 | - | $-2.00 | $-1.09 | $-0.97 | $-1.01 | $-0.69 | $-0.69 | $-0.47 | $-0.61 | $-0.63 | $-0.60 | $-0.49 |
| Avg Forecast | $-1.13 | $-1.14 | $-1.17 | $-1.23 | $-1.41 | $-1.41 | $-1.38 | $-1.40 | $-1.42 | $-1.40 | $-1.22 | $-1.37 | $-1.44 | $-1.50 | $-1.32 | $-1.40 | $-1.38 | $-1.29 | $-1.30 | $-1.11 | $-0.95 | $-0.85 | $-0.63 | $-0.66 | $-0.60 | $-0.59 | $-0.69 | $-0.43 | $-0.56 | $-0.62 |
| High Forecast | $-1.13 | $-1.14 | $-1.17 | $-1.23 | $-1.41 | $-1.41 | $-1.38 | $-1.40 | $-1.42 | $-1.07 | $-1.22 | $-1.37 | $-0.99 | $-1.21 | $-1.32 | $-1.40 | $-1.38 | $-1.29 | $-1.30 | $-0.17 | $-0.14 | $-0.13 | $-0.10 | $-0.10 | $-0.09 | $-0.09 | $-0.11 | $-0.07 | $-0.09 | $-0.09 |
| Low Forecast | $-1.13 | $-1.14 | $-1.17 | $-1.23 | $-1.41 | $-1.41 | $-1.38 | $-1.40 | $-1.42 | $-1.55 | $-1.22 | $-1.37 | $-1.62 | $-1.78 | $-1.32 | $-1.40 | $-1.38 | $-1.29 | $-1.30 | $-2.60 | $-2.22 | $-1.98 | $-1.49 | $-1.54 | $-1.41 | $-1.38 | $-1.62 | $-1.01 | $-1.32 | $-1.45 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 1.06% | 0.75% | 1.04% | 1.14% | - | 1.80% | 1.15% | 1.15% | 1.59% | 1.05% | 1.15% | 0.80% | 0.88% | 1.46% | 1.07% | 0.79% |
According to undefined Wall Street analysts, Intellia Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NTLA previous annual EPS of $NaN (undefined).
Intellia Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics | $4.02 | $39.75 | 888.81% | Buy |
| NTLA | Intellia Therapeutics | $22.07 | $119.16 | 439.92% | Buy |
| EDIT | Editas Medicine | $3.95 | $17.00 | 330.38% | Buy |
| PRME | Prime Medicine | $4.09 | $17.25 | 321.76% | Buy |
| VERV | Verve Therapeutics | $5.50 | $21.50 | 290.91% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| CRSP | CRISPR Therapeutics | $48.94 | $109.58 | 123.91% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| DNA | Ginkgo Bioworks | $6.32 | $7.34 | 16.14% | Buy |
| VRTX | Vertex Pharmaceuticals | $485.37 | $381.05 | -21.49% | Buy |
NTLA Forecast FAQ
Is Intellia Therapeutics a good buy?
Yes, according to 13 Wall Street analysts, Intellia Therapeutics (NTLA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 100.00% of NTLA's total ratings.
What is NTLA's price target?
Intellia Therapeutics (NTLA) average price target is $119.16 with a range of $24 to $252, implying a 439.92% from its last price of $22.07. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Intellia Therapeutics stock go up soon?
According to Wall Street analysts' prediction for NTLA stock, the company can go up by 439.92% (from the last price of $22.07 to the average price target of $119.16), up by 1041.82% based on the highest stock price target, and up by 8.74% based on the lowest stock price target.
Can Intellia Therapeutics stock reach $30?
NTLA's average twelve months analyst stock price target of $119.16 supports the claim that Intellia Therapeutics can reach $30 in the near future.
What are Intellia Therapeutics's analysts' financial forecasts?
Intellia Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $57.26M (high $57.26M, low $57.26M), average EBITDA is $-57.259M (high $-57.259M, low $-57.259M), average net income is $-542M (high $-542M, low $-542M), average SG&A $100.88M (high $100.88M, low $100.88M), and average EPS is $-5.593 (high $-5.593, low $-5.593). NTLA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $30.69M (high $30.69M, low $30.69M), average EBITDA is $-30.688M (high $-30.688M, low $-30.688M), average net income is $-453M (high $-453M, low $-453M), average SG&A $54.07M (high $54.07M, low $54.07M), and average EPS is $-4.672 (high $-4.672, low $-4.672).
Did the NTLA's actual financial results beat the analysts' financial forecasts?
Based on Intellia Therapeutics's last annual report (Dec 2022), the company's revenue was $52.12M, beating the average analysts forecast of $41.18M by 26.58%. Apple's EBITDA was $-445M, beating the average prediction of $-197M by 125.26%. The company's net income was $-490M, beating the average estimation of $-438M by 11.84%. Apple's SG&A was $90.31M, beating the average forecast of $72.55M by 24.48%. Lastly, the company's EPS was $-6.37, beating the average prediction of $-5.077 by 25.47%. In terms of the last quarterly report (Sep 2023), Intellia Therapeutics's revenue was $11.99M, missing the average analysts' forecast of $13.05M by -8.10%. The company's EBITDA was $-122M, beating the average prediction of $-13.048M by 836.69%. Intellia Therapeutics's net income was $-122M, missing the average estimation of $-145M by -15.89%. The company's SG&A was $29.4M, beating the average forecast of $22.99M by 27.90%. Lastly, the company's EPS was $-1.38, missing the average prediction of $-1.498 by -7.91%